Chimeric antigen receptor as well as preparation method and application thereof
By overexpressing the H2AFY2 protein in chimeric antigen receptors, the problem of CAR-T cell depletion was solved, significantly improving its anti-tumor effect and survival, and better than traditional CAR-T cells.
Patent Information
- Application Number
- CN202411264598.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-10
- Publication Date
- 2024-11-12
AI Technical Summary
CAR-T cells are easily depleted when treating solid tumors, resulting in reduced efficacy, and the prior art is difficult to effectively solve this problem.
H2AFY2 was screened as a key factor in resisting CAR-T cell depletion and overexpressing H2AFY2 protein in chimeric antigen receptors, enhancing the antitumor ability of CAR-T cells.
CAR-T cells overexpressing H2AFY2 significantly improved their killing ability to tumor cells, prolonged mouse survival, and reduced the expression of exhaust-related molecules, significantly better than CAR-T cells that did not overexpress H2AFY2.
Smart Images

Figure CN118930661A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of chimeric antigen receptors, and in particular to a chimeric antigen receptor and a preparation method and application thereof. Background Art
[0002] Chimeric antigen receptor (CAR) is a synthetic receptor that consists of four main parts: antigen binding domain, hinge region, transmembrane domain and intracellular signaling domain. Immunotherapy represented by chimeric antigen receptor-modified T (CAR-T) cells has shown good therapeutic effects in the treatment of hematological tumors. Several clinical trials have shown that the complete remission rate of CAR-T cell therapy targeting CD19 in children and adults with relapsed / refractory acute B-lymphocytic leukemia is over 70%-90%.
[0003] CAR-T cells do not respond in the treatment of most patients with solid tumors. The reason is that CAR-T cell exhaustion and the immunosuppressive effect of the microenvironment are important factors that limit the efficacy of solid tumor treatment. Among them, T cell exhaustion is a state in which T cells lose their normal antiviral or anti-tumor ability due to long-term exposure to chronic infection or antigen stimulation. In recent years, studies have shown that T cell exhaustion is a key issue leading to poor efficacy of immunotherapy. At present, existing literature has established T cell exhaustion models based on in vitro and in vivo mouse models and screened exhaustion-related genes, but lacks the key factors that affect CAR-T cell exhaustion in patients with ineffective CAR-T cell therapy in the real world of clinical practice. Summary of the invention
[0004] The purpose of the present invention is to overcome the deficiencies in the prior art and provide a chimeric antigen receptor and a preparation method and application thereof, and to screen out H2AFY2 through clinical patient specimens as a key factor in resisting CAR-T cell exhaustion; H2AFY2 can maintain its anti-tumor ability by inhibiting CAR-T cell exhaustion.
[0005] The present invention is achieved through the following technical scheme: on the one hand, a chimeric antigen receptor is provided, which is sequentially spliced from the N-terminus to the C-terminus with a single-chain antibody ScFv targeting CD19 and / or MESO, a CD28 transmembrane region, a CD28 intracellular domain and a CD3ζ chain, a P2A self-cleaving peptide, and GFP; and a P2A nucleotide sequence and a nucleotide sequence capable of overexpressing the H2AFY2 protein are spliced at the C-terminus of the CD3ζ chain.
[0006] Furthermore, the nucleotide sequence of the H2AFY2 protein is shown in SEQ ID NO.1:
[0007] SEQ ID NO.1:
[0008]
[0009] Through the above technical solution, overexpression can enhance the ability of CAR-T cells to resist exhaustion, thereby enhancing their anti-tumor effect.
[0010] Furthermore, the amino acid sequence of the single-chain antibody ScFv of MESO is shown in SEQ ID NO.2; the amino acid sequence of the single-chain antibody ScFv of CD19 is shown in SEQ ID NO.3.
[0011] SEQ ID NO.2:
[0012] QVQLVQSGAEVKRPGASVQVSCRASGYSINTYYMQWVRQAPGAGLEWMGVINPSGVTSYAQKFQGRVTLTNDTSTNTVYMQLNSLTSADTAVYYCARWALWGDFGMDVWGKGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQSP STLSASIGDRVTITCRASEGIYHWLAWYQQKPGKAPKLLIYKASSLASGAPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQYSNYPLTFGGGTKLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDSEQ IDNO.3:
[0013] EVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEW
[0014] LGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKH
[0015] YYYGGSYAMDYWGQGTSVTVSSGGGGSGGGGSGGGGSDIQMTQTTSSLS
[0016] ASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFS
[0017] GSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEIT
[0018] Furthermore, the P2A nucleotide sequence is shown in SEQ ID NO.4.
[0019] SEQ ID NO.4:
[0020] GGAAGCGGAGCTACTAACTTCAGCCTGCTGAAGCAGGCTGGAGACGTG
[0021] GAGGAGAACCCTGGACCT
[0022] A nucleic acid is also provided, which encodes the chimeric antigen receptor as described above.
[0023] Also provided is a recombinant expression vector or host cell containing the nucleic acid.
[0024] Furthermore, the vector is a lentiviral vector, which also contains a replication initiation site, a 3'LTR and a 5'LTR.
[0025] Furthermore, the host cell is selected from at least one of T cells, NK cells, NKT cells, B cells, and γδT cells.
[0026] A method for preparing the chimeric antigen receptor is provided, comprising the following steps:
[0027] (1) constructing a lentiviral expression vector encoding a chimeric antigen receptor and a lentiviral expression vector encoding H2AFY2;
[0028] (2) co-transfecting the lentiviral expression vector in step (1) with the packaging plasmid into virus packaging cells to prepare recombinant lentiviruses, thereby obtaining recombinant lentiviruses containing a chimeric antigen receptor coding sequence and a recombinant lentivirus containing a H2AFY2 coding sequence;
[0029] (3) introducing the recombinant lentivirus containing the chimeric antigen receptor coding sequence described in step (2) into T cells to prepare T cells expressing the chimeric antigen receptor;
[0030] (4) Transfecting the recombinant lentivirus containing the coding sequence of H2AFY2 described in step (2) into the T cells expressing the chimeric antigen receptor in step (3) to obtain the chimeric antigen receptor T cells.
[0031] Finally, provided is a chimeric antigen receptor, a nucleic acid, a recombinant expression vector or a host cell of the nucleic acid, and a method for preparing the chimeric antigen receptor as described above, and their use in immune cell depletion.
[0032] Beneficial Effects
[0033] When CAR-T cells overexpressing H2AFY2 were stimulated with tumor cells in vitro for multiple rounds, their killing ability was significantly stronger than that of CAR-T cells, and the expression level of TOX, a molecule depleted by H2AFY2-CAR-T cells, was significantly reduced. At the same time, in vivo results showed that CAR-T cells overexpressing H2AFY2 had significantly better anti-tumor effects than CAR-T cells and prolonged the survival of mice. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] Figure 1 Schematic diagram of the main structures of meso CAR, H2AFY2-meso CAR, CD19-CAR and H2AFY2-CD19 CAR plasmids embodied in the present invention;
[0035] Figure 2 The present invention is a schematic diagram of the production efficiency of meso CAR-T, H2AFY2-meso CAR-T, CD19-CAR-T and H2AFY2-CD19CAR-T cells (it can be seen from the figure that the four CAR-T cells have high transfection efficiency);
[0036] Figure 3 The present invention is a statistical diagram showing the short-term tumor cell killing effect of meso CAR-T, H2AFY2-meso CAR-T, CD19-CAR-T and H2AFY2-CD19CAR-T cells (from the statistical diagram, it can be seen that H2AFY2-meso CAR-T and H2AFY2-CD19 CAR-T have higher tumor cell killing ability);
[0037] Figure 4 The present invention embodies the ability of meso CAR-T cells, H2AFY2-meso CAR-T cells and tumor cells to resist exhaustion after multiple rounds of co-incubation (H2AFY2-meso CAR-T cells have a higher ability to resist exhaustion);
[0038] Figure 5 The present invention embodies the statistics of the ability of meso CAR-T, H2AFY2-meso CAR-T, CD19-CAR-T and H2AFY2-CD19CAR-T cells to kill tumor cells in vivo (the left side is the fluorescence graph of H2AFY2-meso CAR-T and H2AFY2-CD19 CAR-T cells killing tumors in vivo, and the right side is the fluorescence statistics graph and the mouse survival graph. From the statistical results, it can be seen that H2AFY2-meso CAR-T and H2AFY2-CD19 CAR-T cells can significantly control tumor growth and prolong mouse survival);
[0039] Figure 6The present invention embodies the ability of T and H2AFY2-T cells to resist exhaustion (the left side is a schematic diagram of an in vitro T cell exhaustion model. The right side shows that the levels of PD-1, TIM3 and TOX expressed by H2AFY2-T cells after in vitro induced exhaustion are reduced, and the results show that the ability of T cells overexpressing H2AFY2 to resist exhaustion is enhanced). DETAILED DESCRIPTION
[0040] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0041] The extracellular antigen binding domain in the present invention may also be referred to as a "single-chain antibody" (scFv), which refers to an antibody fragment having the ability to bind to an antigen, which is formed by connecting the amino acid sequence of the variable region (VL region) of the antibody light chain and the amino acid sequence of the variable region (VH region) of the heavy chain via a hinge. In certain embodiments, the single-chain antibody (scFv) of interest is derived from an antibody of interest. The antibody of interest may be a human antibody, including a human-mouse chimeric antibody and a humanized antibody. The antibody may be secreted or membrane-anchored.
[0042] The nucleotide fragment encoding the protein in the present invention is defined herein as the portion of the nucleic acid sequence that directly determines the amino acid sequence of its protein product (e.g., CAR, monoclonal antibody, hinge region, and transmembrane region). The boundaries of the coding sequence are usually determined by the ribosome binding site (for prokaryotes) immediately upstream of the open reading frame at the 5' end of the mRNA and the transcription termination sequence immediately downstream of the open reading frame at the 3' end of the mRNA. The coding sequence may include, but is not limited to, DNA, cDNA, and recombinant nucleic acid sequences.
[0043] The chimeric antigen receptor polypeptide (CAR) in the present invention is an artificially modified receptor polypeptide that can anchor specific molecules (such as antibodies) that recognize tumor cell surface antigens on immune cells (such as T cells), so that immune cells recognize tumor antigens or viral antigens and kill tumor cells or virus-infected cells. CAR usually includes an optional signal peptide, a polypeptide that binds to a tumor cell membrane antigen such as a single-chain antibody, a hinge region, a transmembrane region, and an intracellular signal region in sequence. Generally, a polypeptide that binds to a tumor cell membrane antigen can bind to a membrane antigen widely expressed by tumor cells with moderate affinity. The polypeptide that binds to a tumor cell membrane antigen can be a natural polypeptide or an artificially synthesized polypeptide.
[0044] The present invention provides a chimeric antigen receptor, which is sequentially spliced from the N-terminus to the C-terminus with a single-chain antibody ScFv targeting CD19 and / or MESO, a CD28 transmembrane region, a CD28 intracellular domain and a CD3ζ chain, a P2A self-cleaving peptide, and GFP; a P2A nucleotide sequence and a nucleotide sequence capable of overexpressing a H2AFY2 protein are spliced at the C-terminus of the CD3ζ chain; wherein the nucleotide sequence of the H2AFY2 protein is as shown in SEQ ID NO.1.
[0045] Based on the above technical solution, the amino acid sequence of the single-chain antibody ScFv of MESO is shown in SEQ ID NO.2; the amino acid sequence of the single-chain antibody ScFv of CD19 is shown in SEQ ID NO.3; and the nucleotide sequence of P2A is shown in SEQ ID NO.4.
[0046] A nucleic acid encoding the chimeric antigen receptor as described above.
[0047] A recombinant expression vector or host cell containing the above nucleic acid; the vector is a lentiviral vector, which also contains a replication initiation site, 3'LTR and 5'LTR.
[0048] Based on the above scheme, the host cell is selected from at least one of T cells, NK cells, NKT cells, B cells, and γδT cells.
[0049] Also provided is a method for preparing the chimeric antigen receptor, comprising the following steps:
[0050] (1) constructing a lentiviral expression vector encoding a chimeric antigen receptor and a lentiviral expression vector encoding H2AFY2;
[0051] (2) co-transfecting the lentiviral expression vector in step (1) with the packaging plasmid into virus packaging cells to prepare recombinant lentiviruses, thereby obtaining recombinant lentiviruses containing a chimeric antigen receptor coding sequence and a recombinant lentivirus containing a H2AFY2 coding sequence;
[0052] (3) introducing the recombinant lentivirus containing the chimeric antigen receptor coding sequence described in step (2) into T cells to prepare T cells expressing the chimeric antigen receptor;
[0053] (4) Transfecting the recombinant lentivirus containing the coding sequence of H2AFY2 described in step (2) into the T cells expressing the chimeric antigen receptor in step (3) to obtain the chimeric antigen receptor T cells.
[0054] Also provided is the use of the chimeric antigen receptor, the nucleic acid, the recombinant expression vector or host cell of the nucleic acid, and the method for preparing the chimeric antigen receptor in immune cell depletion.
[0055] In order to more clearly illustrate the present invention, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the invention. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments in the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention. The experimental methods in the following examples where specific conditions are not specified are generally carried out under conventional conditions or under the conditions recommended by the manufacturer. Unless otherwise stated, all percentages, ratios, proportions or parts are by weight. The reagents and raw materials used in the embodiments and comparative examples of the present invention, unless otherwise specified, can be obtained through commercial channels;
[0056] The main sources of reagents used in the embodiments and experimental examples are as follows:
[0057]
[0058]
[0059] Example 1 (Screening of H2AFY2 from clinical patient specimens as a key factor in resisting CAR-T cell exhaustion)
[0060] The gene number of Homo sapiens H2AFY2: NM-018649.3 and the full-length CDS region were searched on the NCBI website. Primers were designed using SnapGene software and synthesized in the company. The full-length sequence of H2AFY2 was amplified by RTPCR using human T cell cDNA as a template. The sequence is shown in the following SEQ ID NO.1:
[0061]
[0062] Example 2 (Construction of chimeric antigen receptor (CAR) plasmid vector)
[0063] ①Use PCDH plasmid as expression vector and cut the plasmid into linear vector using EcoRI / BamHI restriction endonuclease.
[0064] ② Design primers for H2AFY2 overexpression;
[0065] F: actctagagctagcgaattcatgtcgggccggagtgggaa
[0066] R:ccctcagcggccgcggatcccttggcgtcgagcttggcca
[0067] ③ Use primers to amplify the H2AFY2 fragment synthesized by the company; the amplified fragment contains the target gene and P2A sequence, and contains linear vector homologous sequences at both ends.
[0068] ④Use homologous recombination enzyme to connect the linear vector and the target gene.
[0069] ⑤Transform, pick single clone colonies for amplification, send to the company for sequencing, and retain the strains with correct sequences.
[0070] ⑥ Amplify the bacterial strain with the correct sequence and extract the plasmid.
[0071] ⑦ Obtain the H2AFY2-meso CAR overexpression plasmid (see Figure 1 A) and overexpression of H2AFY2-CD19 CAR plasmid (see Figure 1 Specifically, the H2AFY2 gene sequence obtained by RT-PCR was connected to the back of meso-CAR or CD19-CAR through the P2A sequence, and the construction was confirmed to be successful after RT-PCR and sequencing identification, and the H2AFY2-mesoCAR vector and H2AFY2-CD19 CAR vector were obtained. The structure diagram is shown in Figure 1 .
[0072] Example 3 (H2AFY2-meso CAR lentivirus preparation)
[0073] ①Plasmid transformation
[0074] Pipette 1 μL of plasmid into competent cells DH5α, flick twice and place on ice for 30 min; heat shock at 42°C for 45 s, place back on ice for 2 min; add 500 μL of LB medium without ampicillin, shake at 37°C for 1 h; pipette 100 μL of bacterial solution, streak it on an LB culture plate, and culture it upside down at 37°C for 12-16 h; pick a single colony and transfer it to 5 mL of LB medium containing ampicillin, and shake it at 37°C for 12-16 h.
[0075] ②Plasmid extraction
[0076] Plasmid extraction was performed according to the instructions of the plasmid extraction kit, which is briefly described as follows: take out the bacterial liquid after amplification on the shaker, centrifuge and discard the supernatant; add 500μL P1 solution, mix by blowing, then add 500μL P2 solution, invert and mix; add 500μL P4 solution, mix and let stand for 10 minutes; centrifuge and aspirate the supernatant and add it to the filter column, centrifuge and collect the filtrate; add 0.3 times the volume of isopropanol, mix and add to the adsorption column, centrifuge and discard the waste liquid; add 500μL PD solution, centrifuge and discard the waste liquid; add 600μL PW solution, centrifuge and discard the waste liquid; idle for 2 minutes and discard the waste liquid; add 100μL eluent TB to the middle of the adsorption column, let stand at room temperature, centrifuge and collect the filtrate below, which is the plasmid solution.
[0077] ③ Lentivirus packaging
[0078] An appropriate amount of 293T cells were inoculated into a 10 cm cell culture dish and cultured at 37°C. When the confluency reached 80%, plasmid transfection was performed. The transfection system was as follows: 5 μg of main plasmid, 3 μg of PSPAX2, and 2 μg of PMD2.G plasmid were added to 500 μL jetPRIME buffer and vortexed to mix. Then, 20 μL of jetPRIME transfection reagent was added and vortexed to mix. The culture was allowed to stand at room temperature for 10 min, and then slowly added to the 293T cells. After 6 h, fresh DMEM high-glucose complete medium was replaced. The culture was carried out at 37°C and the supernatant was collected for 48 h as the viral supernatant.
[0079] Example 4 (CAR-T cell preparation)
[0080] ① Magnetic separation of healthy human CD3 + T cells were obtained by density gradient centrifugation to obtain human peripheral blood mononuclear cells (PBMCs). MACS buffer was added to the PBMCs to resuspend them and centrifuged for 5 min at 1500 rpm, with a speed of 9 for ascending and 9 for descending. The supernatant was discarded after centrifugation. Human CD3 sorting magnetic beads were added to the cell pellet (1×10 7 Add 80 μL buffer and 20 μL magnetic beads to the cells, mix well and incubate at 4°C for 15 min. Place the LS column in the magnetic pole and sort the obtained CD3 +After washing, T cells were activated with CD3 and CD28 monoclonal antibodies for 48 h.
[0081] ②Viral infection
[0082] Take 1×10 6 Activated human CD3 + T cells were resuspended with 3 mL of the corresponding virus supernatant after centrifugation, polybrene (5 μg / mL) was added, and then spread into a 12-well plate and centrifuged for 2 h at 1000 g, with a speed of 5 and a speed of 1. After centrifugation, the supernatant was carefully discarded and replaced with fresh RPMI-1640 complete medium, cultured at 37°C for subsequent experiments.
[0083] Based on the above scheme, Figure 2 A schematic diagram of the production efficiency of meso CAR-T, H2AFY2-meso CAR-T, CD19-CAR-T and H2AFY2-CD19 CAR-T cells is provided. It can be seen from the figure that Figure A is the transfection efficiency of meso CAR-T and H2AFY2-meso CAR-T cells; Figure B is the transfection efficiency of CD19 CAR-T and H2AFY2-CD19 CAR-T cells. All four CAR-T cells have high transfection efficiency.
[0084] Example 5 (Selection of target cells and detection of CAR-T killing function)
[0085] ① Co-incubation of CAR-T cells and tumor cells
[0086] The constructed CAR-T cells and H322 or Raji cells with high expression of meso or CD19 in the logarithmic growth phase were taken and counted; CAR-T cells and tumor cells were plated into 96-well plates at different effector-target ratios; after 24 hours, cells and culture supernatant were collected for corresponding detection.
[0087] ② Detection of tumor cell lysis rate
[0088] All cells at the bottom and in the suspension were collected, centrifuged and washed twice with PBS, and apoptosis was detected by flow cytometry (Annexin V staining and PI was added before loading); Figure 3As shown, the present invention provides statistical graphs of the short-term tumor cell killing effects of meso CAR-T, H2AFY2-mesoCAR-T, CD19-CAR-T and H2AFY2-CD19 CAR-T cells, wherein Figure A is a graph showing the lysis rate of tumor cells H322 detected by co-incubating CAR-T cells with H322 cells for 6 hours; Figure B is a graph showing the lysis rate of Raji cells detected by co-incubating CAR-T cells with Raji cells for 6 hours; it can be seen from the statistical graphs that H2AFY2-meso CAR-T and H2AFY2-CD19CAR-T have higher tumor cell killing abilities.
[0089] Example 6 (Detection of immune cell resistance to exhaustion)
[0090] Take the constructed CAR-T cells and tumor cells in the logarithmic growth phase and count them; plate an appropriate amount of CAR-T cells and tumor cells in a 24-well plate at a 5:1 effector-target ratio; after 48 hours, sort out the CAR-T cells, count them, and take a small amount of cells for flow cytometry detection of molecular expression, collect the tumor cells at the bottom and in the suspension, and perform flow cytometry detection of apoptosis (stain with Annexin V, and add PI before loading). This is the first round of incubation and detection; the remaining CAR-T cells are again plated in a 24-well plate with fresh tumor cells at a 5:1 effector-target ratio for the second round of co-incubation experiment and detection, and repeat 4 rounds. Based on Figure 4 The ability of CAR-T cells to resist exhaustion after multiple rounds of co-incubation of meso CAR-T and H2AFY2-meso CAR-T cells with tumor cells. Figure A is a schematic diagram of multiple rounds of co-incubation of CAR-T cells with tumor cells. Figure B is the lysis rate of tumor cells after 2 days of co-incubation of tumor cells with CAR-T cells in each round. Figures C and D are flow cytometry tests of IFN-g secretion and TOX expression levels of CAR-T cells after 2 days of co-incubation of tumor cells with CAR-T cells in each round. H2AFY2-meso CAR-T cells have a higher ability to resist exhaustion.
[0091] Example 7 (In vivo anti-tumor effect)
[0092] ①Establishment and treatment of lymphoma-bearing mouse model
[0093] Six-week-old NOD-SCID mice were intravenously infused with the prepared Raji (luciferase-tagged) tumor cells. The cell inoculation volume per mouse was 2×10 5 One week later, small animal imaging was performed to detect tumor formation, and CAR-T cells were reinfused on the same day. The mice were divided into three groups: Mock (empty plasmid control), CD19 CAR-T cells, and H2A-CD19 CAR-T cells. Each mouse was reinfused with 1×10 6cells; the mice were photographed and their survival was recorded every week, and peripheral blood was drawn from the mice on the 21st day for CAR-T cell function testing.
[0094] ②Establishment and treatment of solid tumor-bearing mouse models
[0095] (1) Digestion of H322-luc cell line in logarithmic growth phase and adjust the cell density to 2×106 cells / mL;
[0096] (2) Six-week-old NOD-SCID mice were subcutaneously infused with the prepared tumor cells at 100 μL per mouse, i.e., the cell inoculation volume per mouse was 2 × 105;
[0097] (3) Four days after cell infusion, small animal imaging was performed to detect tumor formation, and CAR-T cells were reinfused on the same day. The mice were divided into three groups: Mock (empty plasmid control), Meso CAR-T cells, and H2A-Meso CAR-T cells. Each mouse was reinfused with 1×106 cells.
[0098] (4) The mice were photographed and their survival was recorded every week. On the 18th day, the spleen and tumor tissues of the mice were taken for CAR-T cell function testing. Figure 5 As shown, the present invention provides statistics on the ability of meso CAR-T, H2AFY2-meso CAR-T, CD19-CAR-T and H2AFY2-CD19 CAR-T cells to kill tumor cells in vivo. Figures A and C are statistical results of imaging fluorescence values of tumor-bearing mice after infusion of CAR-T cells; Figures B and D are statistical graphs of mouse survival; It can be seen from the statistical results that infusion of H2AFY2-meso CAR-T and H2AFY2-CD19 CAR-T cells can significantly control tumor growth and prolong mouse survival.
[0099] Example 8 (Ability of T cells overexpressing H2AFY2 to resist exhaustion)
[0100] To construct an in vitro induced depletion model, human CD8 + T cells were stimulated and activated with CD3 and CD28 monoclonal antibodies for 48 h, and the H2AFY2 overexpressing plasmid was transfected into activated CD8 + T cells were stimulated in vitro with CD3 monoclonal antibody and IL-2. Cells were collected on day 10 and CD8 + T cells and CD8 overexpressing H2AFY2 + The levels of T cell expression of exhaustion molecules PD-1, TIM-3, and TOX; e.g. Figure 6As shown, the present invention provides the ability of T and H2AFY2-T cells to resist exhaustion. Figure A is a schematic diagram of an in vitro T cell exhaustion model; Figure B is a flow cytometry analysis of CD8 + The average fluorescence intensity of PD-1, TIM-3 and TOX expressed by T cells; it can be seen from the figure that after in vitro induced exhaustion, the levels of PD-1, TIM3 and TOX expressed by H2AFY2-T cells decreased, indicating that the ability of T cells overexpressing H2AFY2 to resist exhaustion is enhanced.
[0101] Comparative Example 1
[0102] meso CAR-T cells were co-incubated with tumor cells H322 at an effector-target ratio of 5:1 for 2 days, and tumor cells were collected and their lysis rate was detected by Annexin-V / PI staining; the level of IFN-γ secretion and TOX expression of CAR-T cells were also detected. After co-incubation, CAR-T cells were collected and co-incubated with H322 cells for a second round of 2 days to detect the tumor cell lysis rate and the ability of CAR-T cells to express depletion molecules and secrete proinflammatory cytokines IFN-γ; 4 rounds of co-incubation were performed in sequence for detection.
[0103] Comparative Example 2
[0104] An in vitro induced exhaustion model was constructed. After T cells were activated for 48 hours, they were repeatedly stimulated with CD3 monoclonal antibody and IL-2. The cells were collected and flow cytometry was used to detect the levels of PD-1, TIM-3 and TOX expressed by T cells.
[0105] Effect Example
[0106] From the above-mentioned Examples 1 to 8 and Comparative Examples 1-2, it can be seen that the T cells or CAR-T cells overexpressing H2AFY2 of the present invention have the ability to resist exhaustion. Further in vivo experiments show that CAR-T cells overexpressing H2AFY2 significantly inhibit tumor growth and prolong their survival, and H2AFY2 can enhance its anti-tumor effect by resisting T cell exhaustion.
[0107] Finally, it should be noted that the above is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, it is still possible for those skilled in the art to modify the technical solutions described in the aforementioned embodiments or to make equivalent substitutions for some of the technical features therein. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A chimeric antigen receptor, characterized in that From the N-terminus to the C-terminus, a single-chain antibody ScFv targeting CD19 and / or MESO, a CD28 transmembrane region, a CD28 intracellular domain and a CD3ζ chain, a P2A self-cleaving peptide, and GFP are sequentially spliced; a P2A nucleotide sequence and a nucleotide sequence capable of overexpressing the H2AFY2 protein are spliced at the C-terminus of the CD3ζ chain.
2. The chimeric antigen receptor according to claim 1, characterized in that The nucleotide sequence of the H2AFY2 protein is shown in SEQ ID NO.
1.
3. The chimeric antigen receptor according to claim 1, characterized in that The amino acid sequence of the single-chain antibody ScFv of MESO is shown in SEQ ID NO.2; the amino acid sequence of the single-chain antibody ScFv of CD19 is shown in SEQ ID NO.
3.
4. The chimeric antigen receptor according to claim 1, characterized in that The P2A nucleotide sequence is shown in SEQ ID NO.
4.
5. A nucleic acid, characterized in that It encodes the chimeric antigen receptor according to any one of claims 1 to 4.
6. A recombinant expression vector or host cell containing the nucleic acid of claim 5. 7 . The recombinant expression vector or host cell according to claim 6 , wherein the vector is a lentiviral vector, which further contains replication initiation sites 3′LTR and 5′LTR.
8. The recombinant expression vector or host cell according to claim 6, characterized in that: The host cell is selected from at least one of T cells, NK cells, NKT cells, B cells, and γδT cells.
9. A method for preparing the chimeric antigen receptor according to any one of claims 1 to 4, characterized in that: The following steps are involved: (1) constructing a lentiviral expression vector encoding a chimeric antigen receptor and a lentiviral expression vector encoding H2AFY2; (2) co-transfecting the lentiviral expression vector in step (1) with the packaging plasmid into virus packaging cells to prepare recombinant lentiviruses, thereby obtaining recombinant lentiviruses containing a chimeric antigen receptor coding sequence and a recombinant lentivirus containing a H2AFY2 coding sequence; (3) introducing the recombinant lentivirus containing the chimeric antigen receptor coding sequence described in step (2) into T cells to prepare T cells expressing the chimeric antigen receptor; (4) Transfecting the recombinant lentivirus containing the coding sequence of H2AFY2 described in step (2) into the T cells expressing the chimeric antigen receptor in step (3) to obtain the chimeric antigen receptor T cells.
10. Use of the chimeric antigen receptor according to any one of claims 1 to 4, the nucleic acid according to claim 5, the recombinant expression vector or host cell of the nucleic acid according to claim 6, and the method for preparing the chimeric antigen receptor in immune cell depletion.
